GUANGZHOU, China, June 20, 2025 /PRNewswire/ -- As the 137th China Import and Export Fair (Canton Fair) successfully concluded on May 5, its commitment to building a "never-ending" trade platform was more evident than ever. The event saw a record-breaking turnout, with over 280,000 overseas buyers from 219 countries and regions attending in person, up 17.3% from 135th session. Notably, the Fair also attracted 527,185 online participants from 229 countries and regions, highlighting the significant role of digital engagement in expanding its global reach. This impressive online participation underscores the Fair's evolution into a dynamic, year-round business ecosystem, seamlessly blending physical and virtual experiences to foster international trade.
A key highlight of the 137th Canton Fair was the continued optimization of the Fair's digital infrastructure. The official Canton Fair online exhibition platform attracted 4.37 million cumulative visits to exhibitor stores, reinforcing its role as a vital hub for global trade connections. Designed to bridge time zones and geographical boundaries, the platform enables buyers and suppliers to begin negotiations before arriving on-site and continue seamlessly after the physical exhibition ends.
Building on momentum from previous editions, the Canton Fair has upgraded its mobile application by launching two tailored versions: one for buyers and one for suppliers. The buyer version enhances sourcing efficiency through improved search and recommendation engines, a trade matchmaking function, and added services such as e-badge scanning for exchanging digital business cards, invitation letter applications, and translator bookings. The supplier version focuses on supporting real-time trade dialogue, offering practical tools such as buyer reception aids, note-taking features, and integrated trade matchmaking services.
These upgraded apps serve as all-in-one trade tools, streamlining everything from itinerary planning to lead follow-up. By mid-June, the apps had been downloaded over 350,000 times.
In addition, the Fair hosted a series of online industry-specific activities and matchmaking events, fostering more effective online connections between global buyers and Chinese suppliers.
The Canton Fair is evolving beyond its traditional role as a trade exhibition, transforming it into a year-round global business ecosystem. Through upgraded digital tools, enhanced mobile app functionality, and an expanded online engagement strategy, the Fair now facilitates continuous trade matchmaking and seamless buyer-supplier interaction. This digital transformation showcases how technology can extend the impact of physical events, creating an always-on platform that drives international business growth beyond the exhibition period.
To download the Canton Fair App, please visit https://cief.cantonfair.org.cn/en/app/appintro.html.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Canton Fair Builds Year-Round Trade Ecosystem with Upgraded Digital Platform and Dual-Version App
SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- Curie Oncology, one of Southeast Asia's fastest-growing private oncology networks, has partnered with Singapore-based health-tech company Oncoshot to deploy AI-powered clinical research tools that help patients gain faster access to clinical trials.
The partnership marks one of the first real-world implementations of oncology-focused AI within a regional private cancer group, complementing earlier deployments across Singapore's public healthcare system.
Curie Oncology: using AI to bring more trials to patients
Curie Oncology currently runs numerous clinical trials across Singapore and Malaysia. As the group expands its research footprint, the volume of data required to identify eligible patients has increased significantly.
Digitalisation in healthcare has generated large volumes of data with valuable clinical insights. This information ranges from structured datasets like lab results to unstructured content such as free-text notes created inside and outside clinical environments. Yet over 80% of health data is unstructured, making it difficult for research teams to process efficiently or consistently. These limitations create significant barriers for researchers who need reliable, analysis-ready information.
Through the partnership, Curie Oncology is now using Oncoshot's AI tools to rapidly structure and analyse clinical data, enabling its oncologists and research teams to identify eligible patients sooner and offer access to ongoing trials more efficiently.
"Oncoshot helped us restructure our rich clinical and genomic data. We can now use natural language to query this information, enabling us to match patients to innovative therapies, improve patient outcomes, and perform cost-benefit analysis," said Dr Toh Chee Keong, medical oncologist and head of research at Curie Oncology.
AI as an enabler: Oncoshot's role in supporting Curie's research teams
Oncoshot's platform functions as a secure, behind-the-scenes engine that converts unstructured oncology documents into research-ready datasets. During Curie Oncology's rollout, the AI system:
- Extracted and de-identified data with over 95% accuracy, even across varied source systems
- Allowed research coordinators to spend more time on patient-facing and trial-critical tasks, instead of repetitive data processing
Oncoshot's role is to support, not replace, Curie's clinical research processes. The AI system helps teams screen faster, run feasibility checks more consistently, and scale their research programmes without requiring proportional increases in manpower.
"Our focus is to enable clinicians and research staff to do what they do best: care for patients and run high-quality clinical studies," said Dr Huren Sivaraj, CEO and head of clinical AI at Oncoshot. "AI simply removes the manual bottlenecks that make oncology research and access to innovative trials so resource intensive."
Public and private sector adoption
Curie Oncology is among the first private oncology networks in Asia to deploy Oncoshot's AI platform, extending the company's work with earlier public-facing collaborations across Singapore's cancer research ecosystem.
This includes earlier collaborations such as the 2022 project with Icon Cancer Centre and Roche to digitise genomic data, a workflow that has since been fully automated, as well as deployments with Tan Tock Seng Hospital and the National Cancer Centre Singapore which were highlighted in presentations at the International Association of Cancer Registries (IACR) 2025.
Together, these implementations illustrate how AI can support both public and private cancer institutions in processing unstructured oncology data securely and efficiently. Oncoshot's federated architecture ensures that raw patient data remains within each institution's environment, while maintaining compliance with HIPAA, GDPR, and Singapore PDPC regulations.
About Curie Oncology
Curie Oncology is a multi-site regional oncology group operating across Singapore, Malaysia, and the Philippines, with active collaborations in Indonesia and Vietnam. With a strong emphasis on clinical research, Curie runs numerous ongoing studies, providing patients with access to new therapies and precision oncology approaches.
About Oncoshot
Oncoshot is an oncology-focused AI company that helps hospitals and cancer centres transform unstructured clinical data into secure, analysis-ready datasets. Its in-premise medical LLM and federated architecture reduce friction in data extraction and standardisation, giving clinical and research teams faster access to the information needed for feasibility assessment, study planning, and real-world evidence generation.
By strengthening the data foundations that underpin oncology research, Oncoshot enables partners to accelerate cancer R&D and improve patient access to innovative treatments.
Visit www.oncoshot.com for more information.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Curie Oncology and Oncoshot Deploy AI to Improve Patient Outcomes in Asia
